GlobalData has released its pharma report, "PharmaPoint: Migraine - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.
Full Report Details at
- http://www.fastmr.com/prod/804448_pharmapoint_migraine_current_and_future_players.aspx?afid=101
Scope
* Investigation of current and future market competition for Migraine
* Competitor assessment
* Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
* Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis
Reasons to Get this Report
* Gain a high level view of the trends shaping and driving Migraine market
* Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
* Create an effective counter-strategy to gain a competitive advantage against those currently in the market
* What's the next big thing in the global Migraine market landscape? Identify, understand and capitalize
Companies Mentioned in this Report: GlaxoSmithKline, AstraZeneca, Merck, Vernalis, Almirall, Pfizer, Zogenix, NuPathe, Allergan, RedHill Biopharma, OptiNose, CoLucid Pharmaceuticals, SUDA, Revance Therapeutics, NeurAxon
Report Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 GlaxoSmithKline
4.3.2 AstraZeneca
4.3.3 Merck
4.3.4 Vernalis
4.3.5 Almirall
4.3.6 Pfizer
4.3.7 Zogenix
4.3.8 NuPathe
4.3.9 Allergan
4.3.10 RedHill Biopharma
4.3.11 OptiNose
4.3.12 CoLucid Pharmaceuticals
4.3.13 SUDA
4.3.14 Revance Therapeutics
4.3.15 NeurAxon
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Diagnosed Migraine Patients
5.4.2 Percent Drug-treated Patients
5.4.3 General Pricing Assumptions
5.4.4 Generic Erosion
5.5 Physicians and Specialists Included in this Study
5.6 Survey of Prescribing Physicians
5.7 About the Authors
5.7.1 Author
5.7.2 Reviewer
5.7.3 Global Head of Healthcare
5.8 About GlobalData
5.9 Disclaimer
List of Tables
1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for Migraine, 2012-2023
Table 2: Migraine Market - Drivers and Barriers, 2012-2023
Table 3: Key Companies in the Migraine Market, 2013
Table 4: GSK's Migraine Portfolio Assessment, 2013
Table 5: GSK SWOT Analysis, 2013
Table 6: AstraZeneca's Migraine Portfolio Assessment, 2013
Table 7: AstraZeneca SWOT Analysis, 2013
Table 8: Merck's Migraine Portfolio Assessment, 2013
Table 9: Merck SWOT Analysis, 2013
Table 10: Vernalis' Migraine Portfolio Assessment, 2013
Table 11: Vernalis SWOT Analysis, 2013
Table 12: Almirall's Migraine Portfolio Assessment, 2013
Table 13: Almirall SWOT Analysis, 2013
Table 14: Pfizer's Migraine Portfolio Assessment, 2013
Table 15: Pfizer SWOT Analysis, 2013
Table 16: Zogenix's Migraine Portfolio Assessment, 2013
Table 17: Zogenix SWOT Analysis, 2013
Table 18: NuPathe's Migraine Portfolio Assessment, 2013
Table 19: NuPathe SWOT Analysis, 2013
Table 20: Allergan's Migraine Portfolio Assessment, 2013
Table 21: Allergan SWOT Analysis, 2013
Table 22: RedHill's Migraine Portfolio Assessment, 2013
Table 23: RedHill SWOT Analysis, 2013
Table 24: OptiNose's Migraine Portfolio Assessment, 2013
Table 25: OptiNose SWOT Analysis, 2013
Table 26: CoLucid Pharmaceuticals' Migraine Portfolio Assessment, 2013
Table 27: CoLucid Pharmaceuticals SWOT Analysis, 2013
Table 28: SUDA's Migraine Portfolio Assessment, 2013
Table 29: SUDA SWOT Analysis, 2013
Table 30: Revance Therapeutics' Migraine Portfolio Assessment, 2013
Table 31: Revance Therapeutics SWOT Analysis, 2013
Table 32: NeurAxon's Migraine Portfolio Assessment, 2013
Table 33: NeurAxon SWOT Analysis, 2013
Table 34: Physicians Surveyed, By Country
List of Figures
1.2 List of Figures
Figure 1: Global Sales for Migraine by Region, 2012-2023
Figure 2: Company Portfolio Gap Analysis in Migraine, 2012-2023
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
read full article